Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

被引：0
|
作者：
Alida C. Fröberg
Marion de Jong
Berthold A. Nock
Wout A. P. Breeman
Jack L. Erion
Theodosia Maina
Marion Verdijsseldonck
Wouter W. de Herder
Aad van der Lugt
Peter P. M. Kooij
Eric P. Krenning
机构：
[1] Erasmus MC University Medical Center Rotterdam,Department of Nuclear Medicine
[2] NCSR “Demokritos”,Molecular Radiopharmacy, I/R
[3] BioSynthema Inc.,RP
[4] Erasmus MC,Department of Internal Medicine
[5] Erasmus MC,Department of Radiology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2009年 / 36卷
关键词：
CCK-2 receptor; Minigastrin; Cholecystokinin; Medullary thyroid carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1265 / 1272
页数：7
相关论文
共 17 条
  • [1] Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
    Froberg, Alida C.
    de Jong, Marion
    Nock, Berthold A.
    Breeman, Wout A. P.
    Erion, Jack L.
    Maina, Theodosia
    Verdijsseldonck, Marion
    de Herder, Wouter W.
    van der Lugt, Aad
    Kooij, Peter P. M.
    Krenning, Eric P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (08) : 1265 - 1272
  • [2] Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma
    Baudin, E
    Lumbroso, J
    Schlumberger, M
    Leclere, J
    Giammarile, F
    Gardet, P
    Roche, A
    Travagli, JP
    Parmentier, C
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (06) : 912 - 916
  • [3] Evaluation of the CCK-2 Receptor Agonist 177Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma - Results of a Phase 0 "Lumed" Study
    Rottenburger, C.
    Nicolas, G.
    McDougall, L.
    Kaul, F.
    Christ, E.
    Cachovan, M.
    Schibli, R.
    Geistlich, S.
    Behe, M.
    Wild, D.
    NEUROENDOCRINOLOGY, 2019, 108 : 229 - 229
  • [4] Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
    Khamla, E.
    Ben Sellem, D.
    Ben Slimene, M. F.
    NEUROENDOCRINOLOGY, 2016, 103 : 59 - 59
  • [5] Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N-Preliminary Proof of the Principle within the "Lumed" Study
    Rottenburger, C.
    Nicolas, G.
    McDougall, L.
    Kaul, F.
    Christ, E.
    Schibli, R.
    Geistlich, S.
    Behe, M.
    Wild, D.
    NEUROENDOCRINOLOGY, 2018, 106 : 257 - 257
  • [6] Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma
    Kwekkeboom, DJ
    Bakker, WH
    Kooij, PPM
    Erion, J
    Srinivasan, A
    de Jong, M
    Reubi, JC
    Krenning, EP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (09) : 1312 - 1317
  • [7] Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid
    Krausz, Y
    Rosler, A
    Guttmann, H
    Ish-Shalom, S
    Shibley, N
    Chisin, R
    Glaser, B
    CLINICAL NUCLEAR MEDICINE, 1999, 24 (04) : 256 - 260
  • [8] Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
    Grossrubatscher, Erika
    Fanciulli, Giuseppe
    Pes, Luca
    Sesti, Franz
    Dolci, Carlotta
    de Cicco, Federica
    Colao, Annamaria
    Faggiano, Antongiulio
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 16
  • [9] Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings
    Adams, S
    Baum, RP
    Hertel, A
    Schumm-Draeger, PM
    Usadel, KH
    Hör, G
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) : 1277 - 1283
  • [10] SOMATOSTATIN RECEPTOR SCINTIGRAPHY AND MAGNETIC-RESONANCE-IMAGING IN RECURRENT MEDULLARY-THYROID CARCINOMA - A COMPARATIVE-STUDY
    DORR, U
    WURSTLIN, S
    FRANKRAUE, K
    RAUE, F
    HEHRMANN, R
    ISER, G
    SCHOLZ, M
    GUHL, L
    BUHR, HJ
    BIHL, H
    HORMONE AND METABOLIC RESEARCH, 1993, 27 : 48 - 55
12